Aventis Pharmaceuticals Products Inc.

Bristol-myers Squibb Pharma Company

Aventis Pharmaceuticals Inc.

James P Sherbine

Benoit J Vanasse

Matthew R Powers

Adam W Sledeski

Walter Rodriguez

Rick G Woodward

Shawn K Pack

Jaan A Pesti

Larry Kenneth Truesdale

James J Mencel

Zofia J Chrzan

Gregory G Kubiak

Robert C Liu

Anthony J Gardetto

Narasimha M Vemuri

Robert E Yule

David Toledo-Velasquez

Kenneth C McNulty

Diane C Salazar

Vincent Windisch

Michael K O'Brien

Diane C Salazar, Deceased

The present invention provides novel processes and intermediates for preparing corticotropin releasing factor (CRF) receptor antagonists having the structure below which are useful in treating CRF-related disorders such as anxiety and depression. 

Process for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof

The present invention provides novel processes and intermediates for preparing corticotropin releasing factor (CRF) receptor antagonists having the structure below which are useful in treating CRF-related disorders such as anxiety and depression 

Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof

STABLE NON-HYGROSCOPIC CRYSTALLINE FORM OF N-&lsqb;N-&lsqb;N-(4-(PIPERIDIN-4-YL)BUTANOYL)-N-ETHYLGLYCYL&rsqb;ASPARTYL&rsqb;-L-&bgr;-CYCLOHEXYL ALANINE AMIDE, INTERMEDIATES THEREOF, AND PREPARATION THEREOF AND OF ANTITHROMBOTIC AZACYCLOALKYLALKANOYL PEPTIDES AND PSEUDOPEPTIDES

Process for preparing 2,4-dihydroxypyridine and 2,4-dihydroxy-3-nitropyridine

The present invention is directed to a process for preparing 2,4-dihydroxy-pyridine comprising heating a compound of the formula A

Process for preparing 2,4- dihydroxypyridine and 2,4- dihydroxy-3-nitropyridine

The invention is directed to improved methods for preparing N6-substituted adenosine derivatives, to intermediates useful therefor and to methods of preparing these intermediates.

Process for preparing N6-substituted adenosine derivatives

The invention is directed to a non-hygroscopic stable crystalline form of the antithrombotic compound N-[N-[N-(4-piperdin-4-yl)butanoyl)-N-ethylglycyl]-(L)-aspartyl]-(L)-.beta. -cyclohexyl-alanine amide, to processes for preparing said stable crystalline form, to a pharmaceutical composition thereof, and intermediates thereof, and the invention is directed also to processes for preparing a compound of the formula ##STR1## wherein: A, B, Z, E.sup.1, E.sup.2, G, R, m, n, and p are as defined herein.

Stable non-hygroscopic crystalline form of

Growing community of inventors

Voorhees, NJ, United States of America

James P Sherbine